1. Predictive Modeling of Drug Effects on Signaling Pathways in Diverse Cancer Cell Lines
   Shital Kumar Mishra et al, 2016, Proceedings of the 7th ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics CrossRef
2. Knockdown delta-5-desaturase promotes the formation of a novel free radical byproduct from COX-catalyzed ω-6 peroxidation to induce apoptosis and sensitize pancreatic cancer cells to chemotherapy drugs
   Xiaoyu Yang et al, 2016, Free Radical Biology and Medicine CrossRef
3. An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors
   Martin Indarte et al, 2019, Cancer Research CrossRef
4. P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer
   Venkatasubbaiah A Venkatesha et al, 2014, Molecular Cancer CrossRef
5. Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors
   Paramita Ray et al, 2016, Oncotarget CrossRef
6. Epidermal growth factor receptor (EGFR)—MAPK—nuclear factor(NF)‐κB—IL8: A possible mechanism of particulate matter(PM) 2.5‐induced lung toxicity
   Seung‐Chan Jeong et al, 2017, Environmental Toxicology CrossRef
7. The cell line models to study tyrosine kinase inhibitors in non-small cell lung cancer with mutations in the epidermal growth factor receptor: A scoping review
   Alessia Belloni et al, 2024, Critical Reviews in Oncology/Hematology CrossRef
8. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model
   Toshiki Iwai et al, 2016, Oncology Reports CrossRef
9. Neoadjuvant therapy for pancreas cancer: Past lessons and future therapies
   Jeffrey M Sutton, 2014, World Journal of Gastroenterology CrossRef
10. In vitro and in vivo anti‐tumour effects of MPT0B014, a novel derivative aroylquinoline, and in combination with erlotinib in human non‐small‐cell lung cancer cells
    An‐Chi Tsai et al, 2014, British Journal of Pharmacology CrossRef